Inflammatory Reaction Due to Ocular Lens Prosthesis Clinical Trial
Official title:
A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Cataract Surgery Patients
This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
All patients received active treatment in this study. Dose group 1 received 114ug of dexamethasone, Dose group 2 received 513ug and Dose group 3 received 684ug. ;